These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11156572)

  • 1. Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats.
    Parker TJ; Della Pasqua OE; Loizillon E; Chezaubernard C; Jochemsen R; Danhof M
    Br J Pharmacol; 2001 Jan; 132(1):151-8. PubMed ID: 11156572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
    Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
    Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat.
    Bol CJJG ; Danhof M; Stanski DR; Mandema JW
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1051-8. PubMed ID: 9399976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
    Lees P; Giraudel J; Landoni MF; Toutain PL
    J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.
    Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI
    Psychopharmacology (Berl); 1999 Jun; 144(3):272-8. PubMed ID: 10435394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat.
    Bouzom F; Laveille C; Merdjan H; Jochemsen R
    J Pharm Sci; 2000 May; 89(5):603-13. PubMed ID: 10756326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
    Cox EH; Kuipers JA; Danhof M
    Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L; Anderer P
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):12-27. PubMed ID: 2883677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine.
    Millan MJ; Schreiber R; Monneyron S; Denorme B; Melon C; Queriaux S; Dekeyne A
    J Pharmacol Exp Ther; 1999 Apr; 289(1):427-36. PubMed ID: 10087034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
    Millan MJ; Brocco M; Gobert A; Schreiber R; Dekeyne A
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1002-14. PubMed ID: 10027837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo.
    Visser SA; Gladdines WW; van der Graaf PH; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2002 Nov; 303(2):616-26. PubMed ID: 12388643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
    Matsubara R
    Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
    Höcht C; Opezzo JA; Bramuglia GF; Taira CA
    Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
    Toutain PL; Lees P
    J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.